Sanofi Video Q&A: CEO Chris Viehbacher Comments on Key Messages from the Investor Relations Seminar

PARIS--(BUSINESS WIRE)-- Sanofi, a global and diversified healthcare leader, held its annual Investor Relations Thematic Seminar, focused this year on the group's strategy and outlook. CEO Chris Viehbacher comments on the key messages to investors.

Click to watch the video:
http://www.eurobusinessmedia.com/Sanofi-video-Q-A-CEO-Chris-Viehbacher-comments-on-key-messages-from-the-Investor-Relations-Seminar?utm_source=ceo-direct&utm_medium=bw

Topics covered in the interview include:

  • Industry resilience
  • Company transformation
  • Growth platforms
  • Genzyme
  • Innovative products
  • Guidance for 2012-2015
  • Shareholder return

About Sanofi:

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Company website: www.sanofi.com



CONTACT:

SANOFI
Investor Relations:
Sébastien Martel
[email protected]
+33 1 53 77 45 45
or
Media Relations:
[email protected]
+33 (0)1 53 77 45 02

KEYWORDS:   United States  Europe  North America  France  New York

INDUSTRY KEYWORDS:   Health  Communications  Public Relations/Investor Relations  Diabetes  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.